Tests sonrotoclax with zanubrutinib for returning mantle cell lymphoma
Compares sonrotoclax plus zanubrutinib with placebo plus zanubrutinib in adults with mantle cell lymphoma.
Plain-language title generated from the registry record
Registry title: A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Key facts
- Where
- Barretos, Belo Horizonte, Campinas, Caxias do Sul, Curitiba, Joinville, Porto AlegreRS, Recife, São Paulo, and Vitória, BrazilSee the 10 sites
- Phase
- Phase 3
Where in Brazil
- Fundacao Pio Xii Hospital de Amor de BarretosBarretos, BrazilNo longer taking part
- Hospital Felicio RochoBelo Horizonte, BrazilNo longer taking part
- Universidade de Campinas Centro de Hematologia E HemoterapiaCampinas, BrazilNo longer taking part
- Fundacao Universidade de Caxias Do SulCaxias do Sul, BrazilNo longer taking part
- Hospital Erasto GaertnerCuritiba, BrazilNo longer taking part
- Instituto Joinvilense de Hematologia e OncologiaJoinville, BrazilNo longer taking part
- Hospital de Clinicas de Porto AlegrePorto AlegreRS, BrazilNo longer taking part
- Hospital Do Cancer de PernambucoRecife, BrazilNo longer taking part
- Hcfmusp Pesquisa Clinica Do Servico de Hematologia E Terapia CelularSão Paulo, BrazilNo longer taking part
- Hospital Santa Rita de Cassia AfeccVitória, BrazilTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- BeOne Medicines
- Trial code
- NCT06742996EU 2024-515593-27-00
- Record updated
- 29 October 2026
- Original description
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.Read full original descriptionShow less
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.
Inclusion: Histologically locally confirmed diagnosis of MCL based on the World Health Organization 2022 classification of Haematolymphoid Tumors (WHO-HAEM5), or based on International Consensus Classification (ICC); Ability to provide archival or fresh tumor tissue for retrospective central confirmation of MCL diagnosis; Received 1 to 5 prior lines of systemic therapy including an anti-CD20 monoclonal antibody (mAb)-based immunotherapy or chemoimmunotherapy and requiring treatment in the opinion of the investigator; Relapsed or refractory disease after the last line of therapy; Measurable disease defined as ≥ 1 nodal lesion that is > 1.5 cm in longest diameter, or ≥ 1 extranodal lesion that is > 1 cm in longest diameter; Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2; Adequate organ function.
Exclusion: Prior therapy with B-cell lymphoma-2 inhibitor (BCL2i); Prior therapy with BTK degraders; Prior therapy with covalent or non-covalent Bruton tyrosine kinase inhibitor (BTKi) unless the participant was intolerant of non-zanubrutinib covalent or non-covalent BTKi. Participants with refractory disease to BTKi therapy or relapse attributed to failure of BTKi therapy are ineligible; Prior autologous stem cell transplantation or chimeric antigen receptor T-cell therapy within 3 months before first dose of study drug; Prior allogeneic stem cell transplant within 6 months of the first dose of the study drug; History of stroke or intracranial hemorrhage within 6 months before first dose of study drug; Note: Other protocol defined Inclusion/Exclusion criteria may apply; Clinically significant cardiovascular disease; Known central nervous system involvement by lymphoma.